Overview
BGMS market data
Price History
BGMS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.37 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.30 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 1.6% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -117.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.57 – $9.52 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.1M · P/B 1.06 · P/S 3.32.
Company News
Bio Green Med Solution Q2 EPS $(0.08) Up From $(0.93) YoY, Sales $336.000KBenzinga · Aug 12, 2026, 9:35 PM
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 27, 2026, 9:09 AM
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning The Merger—PFLC, NUVL, CCRN, and BGMSGlobenewswire Inc · Jun 18, 2026, 11:15 PM
Bio Green Med Solution Surges 172% After Announcing Deal to Acquire Malaysia Waste Tech CompanyBenzinga · Jun 5, 2026, 1:45 PM
Market-Moving News for June 5thBenzinga · Jun 5, 2026, 11:20 AM
Bio Green Med Solution Strikes Business Combination Agreement To Merge With Future NRG; Financial Terms UndisclosedBenzinga · Jun 4, 2026, 8:15 PM
Cyclacel Pharmaceuticals Q1 EPS $(0.04) Up From $(11.52) YoY, Sales $778.000KBenzinga · May 14, 2026, 8:32 PM